Previous studies note that when treated with RT for breast cancer, patients with heterozygous ATM variants may have an increased risk of radiation-induced subcutaneous late tissue effects [13]; whereas, other reports find no evidence of excess radiation-associated toxicity with breast radiotherapy [14]. This evidence concerns the gene ATM and breast cancer.